<DOC>
	<DOCNO>NCT00809562</DOCNO>
	<brief_summary>This study evaluate safety , tolerability efficacy RO4917523 , comparison placebo , patient treatment-resistant depression . Following washout period exist anti-depressant medication , cohorts patient randomized receive daily oral RO4917523 five different dos ( accord safety tolerability observe low dos study ) , placebo . The anticipated time study treatment 10 day ( inpatient unit ) , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study RO4917523 Patients With Treatment Resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<criteria>adult patient , 1865 year age ; recurrent major depressive disorder , without psychotic feature ; least 3 lifetime treatment failure , least 2 must occur within current depressive episode ; baseline minimal severity define HAMD score 18 ; willing hospitalize least 16 consecutive day . history bipolar disorder , schizoaffective disorder schizophrenia ; history psychosis , include psychotic depression ; significant past present neurological disorder , include seizure , stroke and/or head trauma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>